跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 205 条关于
“LFM2-2.6B-MMAI”
全部
205
临床试验
83
药物
71
机构
3
资讯
48
6个月前
Insilico Medicine and Liquid AI Launch Lightweight AI Model for On-Premise Drug Discovery
去年
AI Biomarker Predicts Survival and Treatment Response in Oligometastatic Prostate Cancer
去年
Seagen Secures $2.6B Deal with RemeGen for Novel HER2-Targeting Cancer Drug
5年前
Seagen Secures $2.6B Deal with RemeGen for Novel HER2-Targeting Cancer Drug
7个月前
Inventiva's Lanifibranor Achieves Dual Endpoints in NASH Trial, Analysts Project $2.6B Peak Sales
9个月前
Artera's AI Model Shows Promise for Personalizing Breast Cancer Treatment Decisions
去年
Lundbeck to Acquire Longboard Pharmaceuticals for $2.6 Billion, Bolstering Dravet Syndrome Pipeline
去年
Artera's AI Algorithm Identifies Which Prostate Cancer Patients Benefit from Intensive Therapy, Earning Best of ASCO Recognition
去年
ArteraAI Prostate Test Expands Access with California Lab License
上个月
Insilico Medicine Launches Industry's First Drug Discovery and Development Benchmark-as-a-Service to Validate AI Models Against Real-World Pharmaceutical Data
第 1 页,共 5 页
上一页
下一页